Your Reed Smith bloggers are part of their firm’s Life Sciences Health Industry Group — a collective that includes not only your bloggers’ compatriots in drug/device product liability defense, but esteemed colleagues assisting health and life sciences companies with issues and opportunities related to regulatory compliance, IP, tech, transactions, and many other areas.
We mention this because we recently received an invitation to a free CLE webinar that two of our regulatory colleagues – Celeste Letourneau and Katie Pawlitz – will be presenting on Wednesday, July 11. It’s on “Clinical Trial Contracts and Investigator-Initiated Study Grant Contracts.”
Typically, we try not to be overly shameless with our shameless plugs. We usually restrict ourselves to just letting our loyal readers know about their bloggers’ upcoming speaking engagements or key drug/device defense industry events.
But we found ourselves just so personally interested in this webinar that we couldn’t help but share it with you. Here’s the webinar description:
Understanding the regulatory underpinnings related to the conduct of clinical trials serves to support compliance with applicable laws and promote efficient negotiation. This program is intended to describe the standards, regulations and requirements that are, or should be, addressed in contracts for the conduct of clinical trials to support FDA applications. The speakers will also address the various FDA and health care laws commonly referenced in clinical trials contracts and discuss fraud and abuse considerations related to clinical trial contracts and investigator-initiated study grant contracts, including the Anti-Kickback Statute, as well as transparency laws related to the same, such as the federal Sunshine Act.
The webinar (and CLE credit) are free, but you do have to register, which you can do here.